Update on PET radiopharmaceuticals: Life beyond fluorodeoxyglucose

Radiologic Clinics of North America

Volumn 42, Issue 6, 2004, Pages 1033-1053

  Shiue, Chyng Yann ^a   Welch, Michael J ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2 [(4 FLUOROPHENYL)(PHENYL)METHOXY]ETHYL] 4 (3 PHENYLPROPYL)PIPERAZINE F 18; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 PHENYL 1H 3 BENZAZEPINE; 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 PHENYL 1H 3 BENZAZEPINE C 11; 3 METHYLSPIPERONE; 3 [[4 (4 CHLOROPHENYL) 1 PIPERAZINYL]METHYL] 1H PYRROLO[2,3 B]PYRIDINE; 4 [(3,4 DICHLOROPHENYL)ACETYL] 3 (1 PYRROLIDINYLMETHYL) 1 PIPERAZINECARBOXYLIC ACID METHYL ESTER; 5 (7 BENZOFURANYL) 8 CHLORO 2,3,4,5 TETRAHYDRO 7 HYDROXY 3 METHYL 1H 3 BENZAZEPINE; 5 (7 BENZOFURANYL) 8 CHLORO 2,3,4,5 TETRAHYDRO 7 HYDROXY 3 METHYL 1H 3 BENZAZEPINE C 11; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE C 11; 8 CHLORO 5 (2,3 DIHYDROBENZOFURAN 7 YL) 2,3,4,5 TETRAHYDRO 3 METHYL 1H 3 BENZAZEPIN 7 OL; ALPHA (2,3 DIMETHOXYPHENYL) 1 [2 (4 FLUOROPHENYL)ETHYL] 4 PIPERIDINEMETHANOL; CARBON 11; CPC 222; DEXTRO THREO METHYLPHENIDATE C 11; DIHYDROTETRABENAZINE C 11; DIPRENORPHINE; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; ECOPIPAM; ECOPIPAM C 11; FALLYPRIDE C 11; FLUMAZENIL; FLUORINE 18; FLUORODEOXYGLUCOSE; ISOREMOXIPRIDE C 11; N FLUOROSPIROPERIDOL F 18; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL) CYCLOHEXANECARBOXAMIDE CARBONYL C 11; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; N [2 [4 (4 CHLOROPHENYL)PIPERAZIN 1 YL]ETHYL] 3 METHOXYBENZAMIDE; NAFADOTRIDE C 11; NITROGEN 13; NOMIFENSINE C 11; OXYGEN 15; RACLOPRIDE C 11; RADIOPHARMACEUTICAL AGENT; ROBALZOTAN; ROBALZOTAN C 11; SB 207145; SKF 82957; TRACER; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; APOPTOSIS; ARTICLE; BRAIN FUNCTION; DIAGNOSTIC ACCURACY; DOPAMINE BRAIN LEVEL; DRUG POTENCY; DRUG UPTAKE; HUMAN; HYPOXIA; ISOTOPE LABELING; NEUROLOGIC DISEASE; NONHUMAN; POSITRON; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL;

EID: 5444262034     PISSN: 00338389     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rcl.2004.08.009     Document Type: Review

References (246)

1. 14C-2-deoxy-2-fluoro-D- glucose J Labelled Comp Radiopharm 14 1978 171 183
2. J.S. Fowler, Y.-S. Ding, and N.D. Volkow Radiotracers for positron emission tomography imaging Semin Nucl Med 23 2003 14 27
3. J.S. Fowler, and Y.-S. Ding Chemistry R.L. Wahl J.W. Buchanan Principles and practice of positron emission tomography 2002 Lippincott William and Wilkins Philadelphia 16 47
4. M.J. Welch C.S. Redvanly Handbook of radiopharmaceuticals: radiochemistry and application 2003 John Wiley & Sons West Sussex (UK)
5. N.D. Volkow, J.S. Fowler, S.J. Gatley, J. Logan, G.-J. Wang, and Y.-S. Ding PET evaluation of the dopamine system of the human brain J Nucl Med 37 1996 1242 1256
6. E.S. Garnett, G. Firnau, and C. Nahmias Dopamine visualized in the basal ganglia in living man Nature 305 1983 137 138
7. O.T. DeJesus, C.J. Endres, S.E. Shelton, R.J. Nickles, and J.E. Holden Evaluation of fluorinated m-tyrosine analogues as PET imaging agents of dopamine nerve terminals: comparison with 6-fluorodopa J Nucl Med 38 1997 630 636
8. 11C-labeled L-tyrosine, L-dopa, L-tryptophan and 5-hydroxyl-L-tryptophan Acta Chem Scand A 44 1990 178 182
9. H.N. Wagner, H.D. Burns, R.F. Dannals, D.F. Wong, B. Langstrom, and T. Duelfer Imaging dopamine receptors in the human brain by positron emission tomography Science 221 1983 1264 1266
10. C.-Y. Shiue, J.S. Fowler, A.P. Wolf, D.W. McPherson, C.D. Arnett, and L. Zecca No-carrier-added fluorine-18-labeled N- methylspiroperidol: synthesis and biodistribution in mice J Nucl Med 27 1986 226 234
11. 18F]fluoropropyl)spiroperidol: biodistribution in mice and tomographic studies in a baboon J Nucl Med 28 1987 1164 1170
12. 18F]fluoroalkyl)-spiperone derivatives Appl Radiat Isot 12 1986 1173 1180
13. 2 receptor affinities of derivatives of spiperone containing aliphatic halogens Appl Radiat Isot 12 1986 1181 1188
14. M.J. Welch, D.Y. Chi, C.J. Mathias, M.R. Kilbourn, J.W. Brodack, and J.A. Katyenellenbogen Biodistribution of N-alkyl and N-fluoroalkyl derivatives of spiroperidol: radiopharmaceuticals for PET studies of dopamine receptors Nucl Med Biol 13 1986 523 526
15. 18F]fluoroethyl)spiperone: a new dopamine receptor-binding tracer for positron emission tomography Nucl Med Biol 13 1986 617 624
16. 18F]fluoroethyl)spiperone. A novel ligand for cerebral dopamine receptor studies with PET Life Sci 40 1987 81 88
17. 11C-labelled raclopride, a new potent dopamine receptor antagonist: preliminary PET studies of cerebral dopamine receptors in the monkey Int J Appl Radiat 36 1985 269 273
18. 18F]fluoropropylbenzamides for dopamine D2 receptor studies Nucl Med Biol 19 1992 571 588
19. 18F]fallypride in nonhuman primates Synapse 38 2000 71 79
20. 2 receptors Synapse 15 1993 169 176
21. 3 receptors J Nucl Med 44 2003 293P
22. 2 dopamine receptors J Nucl Med 36 1995 1275 1281
23. 2 receptors Nucl Med Biol 26 1999 725 735
24. 18F-5-OH- FPPAT) in rodents and nonhuman primates Nucl Med Biol 31 2004 303 311
25. S. Zijlstra, G.M. Visser, J. Korf, and W. Vaalburg Synthesis and in vivo distribution in the rat of several fluorine-18 labeled N-fluoroalkylaporphines Appl Radiat Isot 44 No.4 1993 651 658
26. 2 receptors Nucl Med Biol 27 2000 533 539
27. 11C-labeled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography Appl Radiat Isot 37 1986 1039 1043
28. 1 receptor ligand, and preliminary PET investigations Appl Radiat Isot 42 1991 451 455
29. 1-dopamine receptors J Nucl Med 39 1998 2061 2068
30. 11C-raclopride Psychopharmacology (Berl) 92 1987 278 284
31. 18F]fluoro-3-iodopropane for the synthesis of certain dopamine D-1 and benzodiazepine receptor radioligands Nucl Med Biol 17 1990 811 817
32. 11C]NNC 756 Synapse 32 1999 93 109
33. 1 like dopamine receptor ligand binding during altered endogenous dopamine levels in the primate brain Psychopharmacology (Berl) 146 1999 220 227
34. 11C]SKF 82957 as potential PET radioligands Appl Radiat Isot 47 1996 279 284
35. 3 receptors J Nucl Med 44 2003 72P
36. 4 receptor in the primate brain with positron emission tomography Nucl Med Biol 27 2000 707 714
37. 4 antagonists as candidate radioligands Bioorg Med Chem Lett 11 2001 1375 1377
38. 18F]N-3-fluoropropyl-2-β-carbomethoxy-3- β-(4-iodophenyl)nortropane and the first human study with positron emission tomography Nucl Med Biol 23 1996 999 1004
39. 18F]WIN 35,428), a radioligand to study the dopamine transporter with PET: characterization in human subjects Synapse 28 1998 244 250
40. D. Xing, P. Chen, R. Keil, C.D. Kilts, B. Shi, and V.M. Camp Synthesis, biodistribution, and primate imaging of fluorine-18 labeled 2β-carbo- 1′-fluoro-2-propoxy-3β-(4-chlorophenyl)tropanes. Ligands for the imaging of dopamine transporters by positron emission tomography J Med Chem 43 2000 639 648
41. M.M. Goodman, R. Keil, T.M. Shoup, D. Eshima, L. Eshima, and C. Kilts Fluoro-18-FPCT: a PET radiotracer for imaging dopamine transporters J Nucl Med 38 1997 119 126
42. 18F] fluoromethylphenyl)tropanes: specific probes for in vivo quantification of central dopamine transporter sites Nucl Med Biol 26 1999 897 903
43. 18F]N-(3-fluoropropyl)-2-β- carbomethoxy-3-β-(4-bromophenyl) nortropane and the regional brain uptake in non human primate using PET Nucl Med Biol 31 2004 125 131
44. M.R. Kilbourn In vivo radiotracers for vesicular neurotransmitter transporters Nucl Med Biol 24 1997 615 619
45. C.C. Meltzer, G. Smith, S.T. DeKosky, B.G. Pollock, C.A. Mathis, and R.Y. Moore Serotonin in aging, late life depression and Alzheimer disease: the emerging role of functional imaging Neuropsychopharmacology 18 1998 407 430
46. J.K. Staley, R.T. Malison, and R.B. Innis Imaging of serotonergic system: interactions of neuroanatomical and functional abnormalities of depression Biol Psychiatry 44 1998 534 549
47. A. Frazer Antidepression J Clin Psychiatry 58 Suppl 6 1997 9 25
48. N.M. Barnes, and T. Sharp A review of central 5-HT receptors and their function Neuropharmacology 38 1999 1083 1152
49. V.W. Pike Radioligands for PET studies of central 5-HT receptors and re-uptake sites: current status Nucl Med Biol 22 1995 1011 1018
50. 1A receptors in vivo: radioligands, clinical application and drug development [special issue] Nucl Med Biol 27 2000 429 527
51. 1A) receptors in the central nervous system Eur J Nucl Med 28 2001 113 129
52. 18F]MPPF J Nucl Med 41 2000 1830 1835
53. 18F-MPPF binding in the rat hippocampus J Nucl Med 44 2003 1495 1501
54. A. Neumeister, E. Bain, A.C. Nugent, R.E. Carson, D. Bonne, and D.A. Luckenbaugh Reduced serotonin type 1A receptor binding in panic disorder J Neurosci 24 2004 589 591
55. 1A receptor binding in patients with temporal lobe epilepsy Neurology 60 2003 749 756
56. D.F. Wong, H.N. Wagner, R.F. Dannals, J.M. Links, J.J. Frost, and H.T. Ravert Effects of age on dopamine and serotonin receptors measured by positron emission tomography in the living human brain Science 226 1984 1393 1396
57. 2 receptor availability in healthy human subjects Life Sci 56 1995 249 253
58. 2A receptors with carbon-11-MDL 100,907 J Nucl Med 39 1998 208 214
59. 2A receptor system Med Chem Res 6 1996 1 10
60. 4 receptors in the brain J Labelled Comp Radiopharm 46 2003 S56
61. P. Brust, U. Scheffel, and Z. Szabo Radioligands for the study of 5-HT transporter in vivo Idrugs 2 1999 129 145
62. 11C]McN-5652-Z J Labelled Comp Radiopharm 31 1992 841 848
63. 11C](+)McN5652 Synapse 20 1995 37 43
64. 11C](+)McN5652: a serotonin transporter radioligand J Cereb Blood Flow Metab 19 1999 967 981
65. 11C](+)McN5652: assessment of methods J Cereb Blood Flow Metab 20 2000 253 262
66. 11C]McN5652 J Nucl Med 41 2000 1465 1477
67. 11C](+)McN 5652 Biol Psychiatry 51 2002 715 722
68. 18F]fluoroethyl analogue of McN5652 Nucl Med Biol 23 1996 407 412
69. 18F]fluoromethyl-(+)-McN5652, a PET tracer for the serotonin transporter: evaluation in rats Synapse 47 1 2003 45 53
70. R.M. Ferris, L. Brieaddy, N. Mehta, E. Hollingsworth, G. Rigdon, and C. Wang Pharmacological properties of 403U76, a new chemical class of 5-hydroxytryptamine and noradrenaline re-uptake inhibitor J Pharm Pharmacol 47 1995 775 781
71. 11C]IDAM): a new serotonin re-uptake sites tracer for PET studies J Nucl Med 41 2000 241P
72. 11C]ADAM: a potential radioligand for the serotonin transporter exploration by PET J Labelled Comp Radiopharm 44 2001 113 120
73. 11C- labeled 2-(phenylthio)- araalkylamines J Med Chem 43 2000 3103 3110
74. S. Chalon, J. Tarkiainen, L. Garreau, H. Hall, P. Emond, and J. Vercouille Pharmacological characterization of N,N-dimethyl-2-(2-amino-4- methylphenylthio)benzylamine as a ligand of the serotonin transporter with high affinity and selectivity J Pharmacol Exp Ther 304 2003 81 87
75. 11C]AFM) Nucl Med Biol 31 2004 543 556
76. 11C]DAPA) Nucl Med Biol 29 2002 741 751
77. 18F]fluorophenylthio)- benzylamine as a serotonin transporter imaging agent Appl Radiat Isot 58 2003 183 191
78. 18F]-ADAM): an improved PET radioligand for serotonin transporters J Nucl Med 44 2003 1890 1897
79. Y. Huang, Z. Zhu, S.A. Bae, D.-R. Hwang, R. Narendran, and V. Phan Comparison of three F-18 labeled PET ligands for the serotonin transporter: radiosynthesis and in vivo imaging studies in baboon J Labelled Comp Radiopharm 44 2003 S57
80. 18F]ACF (2-[2-amino-4-chloro-5-fluorophenyl] thio)-N,N-dimethyllbenzenemethanamine) J Med Chem 45 2002 4716 4723
81. 18F]-ADAM) as a serotonin transporter imaging agent Appl Radiat Isot 61 2004 1247 1251
82. 18F(2-[(2-Amino-5-fluorophenyl)thio]-N,N-dimethylbenzenmethanamine) as a PET imaging agent for serotonin transporters J Labelled Comp Radiopharm 44 2003 S164
83. 11C]-DASB binding to the human serotonin transporter: modeling strategies J Cereb Blood Flow Metab 21 2001 1342 1353
84. 11C]DASB PET imaging study Am J Psychiatry 158 2001 1843 1849
85. 18F]β(FEZIENT J Labelled Comp Radiopharm 46 2003 S170
86. R.D. Blakely, L.J. De Felice, and H.C. Hartzell Molecular physiology of norepinephrine and serotonin transporters J Exp Biol 196 1994 263 281
87. 3H]desipramine-binding sites in human postmortem brain tissue Neuropsychobiology 23 1990 68 73
88. G.A. Ordway, C.A. Stockmeyer, G.W. Mason, and V. Klimek Pharmacology and distribution of norepinephrine transporters in the human locus coeruleus and raphe nuclei J Neurosci 17 1997 1710 1719
89. J. Backs, A. Haunstetter, S.H. Gerber, J. Metz, M.M. Berst, and R.H. Strasser The neuronal norepinephrine transporter in experimental heart failure: evidence for a posttranscriptional down-regulation J Mol Cell Cardiol 33 2001 461 472
90. V. Klimek, C. Stockmeier, J. Overholser, H.Y. Meltzer, S. Kalka, and G. Dilley Reduced levels of norepinephrine transporters in the locus coeruleus in major depression J Neurosci 17 1997 8451 8458
91. S. Tejani-Butt, J. Yang, and H. Zaffar Norepinephrine transporter sites are decreased in the locus coeruleus in Alzheimer's disease Brain Res 631 1 1993 147 150
92. 11C-labeled desipramine and its metabolite 2- hydroxydesipramine: potential radiotracers for PET studies of the norepinephrine transporter Nucl Med Biol 24 1997 707 711
93. A.A. Wilson, D.P. Johnson, D. Mozley, D. Hussey, N. Ginovart, and J. Nobrega Synthesis and in vivo evaluation of novel radiotracers for the in vivo imaging of the norepinephrine transporter Nucl Med Biol 30 2003 85 92
94. 11C]MeNER Nucl Med Biol 30 2003 707 714
95. Y.-S. Ding, K.S. Lin, V. Garza, P. Carter, D. Alexoff, and J. Logan Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs Synapse 50 2003 345 352
96. M. Schou, C. Halldin, J. Sovago, V.W. Pike, H. Hall, and B. Gulyas PET evaluation of novel radiofluorinated reboxetine analogues as norepinephrine transporter probes in the monkey brain Synapse 53 2004 57 67
97. J.J. Frost PET imaging of the opioid receptor: the early years Nucl Med Biol 28 2001 509 513
98. J.K. Zubieta, R.F. Dannals, and J.J. Frost Gender and age influences on human brain mu-opioid receptor binding measured by PET Am J Psychiatry 156 1999 842 848
99. J.K. Zubieta, Y.R. Smith, J.A. Bueller, Y. Xu, M.R. Kilbourn, and D.M. Jewett Regional mu opioid receptor regulation of sensory and affective dimensions of pain Science 293 2001 311 315
100. J.K. Zubieta, D.A. Gorelick, R. Stauffer, H.T. Ravert, R.F. Dannals, and J.J. Frost Increased mu opioid receptor binding detected by PET in cocaine-dependent men is associated with cocaine craving Nat Med 2 11 1996 1225 1229
101. D.M. Jewett, and M.R. Kilbourn In vivo evaluation of new carfentanil-based radioligands for the mu opiate receptor Nucl Med Biol 31 2004 321 325
102. 18F-cyprodime J Labelled Comp Radiopharm 46 2003 S175
103. S.K. Luthra, V.W. Pike, and F. Brady The preparation of carbon-11 labelled diprenorphine: a new radioligand for the study of the opioid receptor system in vivo J Chem Soc Chem Commun 1985 1423 1425
104. 11C]buprenorphine: a potential radioligand for the study of the opioid receptor system in vivo Appl Radiat Isot 38 1987 65 66
105. 11C]buprenorphine for positron emission tomographic studies of opioid receptors Appl Radiat Isot 41 1990 745 752
106. 11C]diprenorphine) in baboon using PET Nucl Med Biol 18 1991 281 288
107. 11C]methyl]buprenorphine in baboon brain Nucl Med Biol 23 1996 325 331
108. 18F]fluoropropyl)-N-nordiprenorphine: synthesis, anatomical distribution in mice and rats and tomographic studies in a baboon Int J Appl Radiat Instrum 17 1990 217 227
109. 18F] fluoropropyl)N-nordiprenorphine: synthesis and characterization of a new agent for imaging opioid receptors with positron emission tomography J Med Chem 33 1990 1482 1490
110. 11C]DPN in humans J Nucl Med 41 2000 1279 1286
111. 18F]3-acetylcyclofoxy: a high affinity opiate antagonist Int J Appl Radiat Isot 36 1985 429 433
112. 18F]cyclofoxy in long-term, methadone-treated former heroin addicts J Pharm Exp Ther 295 3 2000 1070 1076
113. 11C]GR89696): synthesis and in vivo binding to kappa opiate receptors Nucl Med Biol 26 1999 737 741
114. 11C]methylnaltrindol and PET Synapse 24 1996 19 28
115. E.A. Barnard, P. Skolnick, R.W. Olsen, H. Mohler, W. Sieghart, and G. Biggio International union of pharmacology, XV: subtypes of gamma-aminobutyric acid A receptors: classification on the basis of subunit structure and receptor function Pharmacol Rev 50 1998 291 313
116. M. Gavish, I. Bachman, R. Shoukrun, Y. Katz, L. Veenman, and G. Weisinger Enigma of the peripheral benzodiazepine receptor Pharmacol Rev 51 1999 630 646
117. V.W. Pike, C. Halldin, C. Crouzel, L. Barre, D.J. Nutt, and S. Osman Radiolignads for PET studies of central benzodiazepine receptors and PK (peripheral benzodiazepine) binding sites-current status [review] Nucl Med Biol 20 1993 503 525
118. 11C]flumazenil kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography J Cereb Blood Flow Metab 11 1991 735 744
119. I. Savic, P. Roland, G. Sedvall, S. Pauli, G. Sedvall, and L. Wilen In vivo demonstration of reduced benzodiazepine receptor binding in human epileptic foci Lancet 15 1988 863 866
120. 18F]fluoroethyl)flumazenil to central benzodiazepine receptors measured in living baboon by positron emission tomography Eur J Pharmacol 218 1992 109 115
121. 18F]FFMZ), a potential GABA receptor ligand for PET Nucl Med Biol 31 2004 291 295
122. L. Junck, J.M.M. Olson, B.J. Ciliax, R.A. Koeppe, G.L. Watkins, and D.M. Jewett PET imaging of human gliomas with ligands for the peripheral benzodiazepine binding site Ann Neurol 26 1989 752 758
123. R.B. Banati, J. Newcombe, and R.N. Gunn The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity Brain 123 2000 2321 2337
124. 11C] (R)-PK 11195-PET following herpes encephalitis reveals projected neuronal damage beyond the primary focal lesion Brain 124 2001 2014 2027
125. N.D. Volkow, Y.-S. Ding, J.S. Fowler, and S.J. Gatley Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia Biol Psychiatry 49 2001 211 220
126. W.C. Eckelman Radiolabeled muscarinic radioligands for in vivo studies Nucl Med Biol 28 2001 485 491
127. A. Buck, G.K. Mulholland, S.M. Papadopoulos, R.A. Koeppe, and K.A. Frey Kinetic evaluation of positron-emitting muscarinic ligands employing direct carotid injection J Cereb Blood Flow Metab 16 1996 1280 1287
128. 11C]NMPB and PET Synapse 39 2001 275 287
129. 11C]-N-methyl-4-piperidinyl benzillate. Comparison with cerebral blood flow and cerebral glucose metabolism Ann Nucl Med 12 1998 35 42
130. 11C]4-MPB Synapse 39 2001 182 192
131. M. Gopalakrishnan, and D.L. Donnelly-Roberts Nicotine: therapeutic prospects? Pharm News 5 1998 16 20
132. M.R. Picciotto, M. Zoli, R. Rimondini, C. Lena, L.M. Marubio, and E.M. Pich Acetylcholine receptors containing the beta 2 subunit are involved in the reinforcing properties of nicotine Nature 391 1998 173 177
133. A. Nordberg Human nicotinic receptors-their role in aging and dementia Neurochem Int 25 1994 93 97
134. D.C. Perry, M.I. Davila-Garcia, C.A. Stockmeier, and K.J. Kellar Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies J Pharmacol Exp Ther 289 1999 1545 1552
135. W. Sihver, A. Nordberg, B. Langstrom, A.G. Mukhin, A.U. Koren, and A.S. Kimes Development of ligands for in vivo imaging of cerebral nicotinic receptors Behav Brain Res 113 2000 143 157
136. 11C]cotinine. Preparation, metabolite studies and in vivo distribution in the human brain using PET Int J Radiat Appl Instrum B 19 1992 871 880
137. R.F. Muzic, M.S. Berridge, R.F. Friedland, N. Zhu, and A.D. Nelaon Quantification of specific binding of carbon-11-nicotine in human brain J Nucl Med 39 1998 2048 2054
138. 11C]nicotine in rhesus monkey Nucl Med Biol 26 1999 633 642
139. 18F]N-methyll-NFEP: kinetics, nicotine effect and toxicity Nucl Med Biol 26 1999 139 148
140. M.A. Abreo, N.-H. Lin, D.S. Garvey, D.E. Gunn, A.M. Hettinger, and J.T. Wasicak Novel 3-pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors J Med Chem 39 1996 817 825
141. 18F]fluoro-A-85380 J Nucl Med 40 1999 1374 1380
142. 18F]A-85380) J Labelled Comp Radiopharm XLI 1998 309 318
143. 18F]Fluoro-A-85380: an in vivo tracer for the nicotinic acetylcholine receptor Nucl Med Biol 27 2000 51 56
144. 18F]fluoroo-3-(S)-azetidinylmethoxy)pyridine for PET studies of nicotine acetylcholine receptors Nucl Med Biol 27 2000 381 389
145. 18F]F-A-85380: PET imaging of brain nicotinic acetylcholine receptors and whole body distribution in humans FASEB J 17 2003 1331 1333
146. 2 nicotinicacetylcholine receptor and wide range of lipophilicity: potential probes for imaging with positron emission tomography J Med Chem 47 2004 2453 2465
147. S. Pappata, B. Tavitian, L. Traykov, A. Jobert, A. Dalger, and J.F. Mangin In vivo imaging of human cerebral acetylcholinesterase J Neurochem 67
148. D.E. Kuhl, R.A. Koeppe, S. Minoshima, S.E. Snyder, E.P. Ficaro, and N.L. Foster In vivo mapping of cerebral acetylcholinesterase activity in aging and Alzheimer's disease Neurology 52 1999 691 699
149. H. Shinotoh, H. Namba, K. Fukushi, S. Nagatsuka, N. Tanaka, and A. Aotsuka Progressive loss of cortical acetylcholinesterase activity in association with cognitive decline in Alzheimer's disease: a positron emission tomography study Ann Neurol 48 2000 194 200
150. D.E. Kuhl, S. Minoshima, K.A. Frey, N.L. Foster, M.R. Kilbourn, and R.A. Koeppe Limited donepezil inhibition of acetylcholinesterase measured with positron emission tomography in living Alzheimer cerebral cortex Ann Neurol 48 2000 391 395
151. 18F](+)-4-fluorobenzyltrozamicol and PET in the Rhesus monkey brain J Nucl Med 41 2000 2069 2076
152. K. Shoghi-Jadid, G.W. Small, and E.D. Agdeppa Localization of neurofibrillary tangles and beta-amyloid plaques in the brains of living patients with Alzheimer disease Am J Geriatr Psychiatry 10 2002 24 35
153. W.E. Klunk, H. Engler, A. Nordberg, Y. Wang, G. Blomqvist, and D.P. Holt Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B Ann Neurol 55 2004 306 319
154. 11C-labeled stilbene derivatives as Aβ-aggregate-specific PET imaging agents for Alzheimer's disease Nucl Med Biol 30 2003 565 571
155. 18F-labeled 6-iodo-2-(4′-N,N- dimethylamino)phenylimidazol[1,2-α]pyridine derivatives as prospective radioligands for β-amyloid in Alzheimer's disease J Med Chem 47 2004 2208 2218
156. P. Rigo, P. Paupus, B.L. Kaschten, R. Hustinx, T. Bury, and G. Jerusalem Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose Eur J Nucl Med 23 1996 1641 1674
157. E.K.J. Pauwels, M.J. Ribeiro, J.H.M.B. Stoot, V.R. McCready, M. Bourguignon, and B. Maziere FDG accumulation and tumor biology Nucl Med Biol 25 1998 317 322
158. R.E. Coleman FDG imaging Nucl Med Biol 27 2000 689 690
159. G.L. Stocklin Is there a future for clinical fluorine-18 radiopharmaceuticals (excluding FDG)? Eur J Nucl Med 25 1998 1612 1616
160. 18F-labeled radiopharmaceuticals for PET in oncology, excluding FDG Nuc Med Biol 27 2000 103 112
161. P.L. Jager, W. Vaalburg, J. Pruim, E.G.E. de Vries, K.-J. Langen, and D.A. Piers Radiolabeled amino acids: basic aspects and clinical applications in oncology J Nucl Med 42 2001 432 445
162. P. Laverman, O.C. Boerman, F.H.M. Corstens, and W.J.G. Oyen Fluorinated amino acids for tumor imaging with positron emission tomography Eur J Nucl Med 29 5 2002 681 690
163. 11C]leucine and PET: methods, model and results in animals and humans J Cereb Blood Flow Metab 9 1989 446 460
164. C.B. Smith, G.E. Deibler, N. Eng, K. Schmidt, and L. Sokoloff Measurement of local cerebral protein synthesis in vivo: influence of recycling of amino acids derived from protein degradation Proc Natl Acad Sci U S A 85 1988 9341 9345
165. 11C]methyl-L- and D-methionine into a malignant glioma Eur J Nucl Med 13 1987 103 105
166. 11C]methionine J Comput Assist Tomogr 11 1987 384 389
167. 18F] fluoroethyl)-L- tyrosine for tumor imaging J Nucl Med 40 1999 205 212
168. 18F]fluoromethyl-L-tyrosine as tumor imaging tracers by PET Nucl Med Biol 31 2004 191 198
169. 3H-thymidine incorporation into DNA Ann N Y Acad Sci 77 1959 803 820
170. 11C-thymidine Proc Natl Acad Sci U S A 69 1971 988 989
171. 18F]-5-FUR) as a probe for measuring RNA synthesis and tumor growth rates in vivo. Proceedings of the Second International Symposium on Radiopharmaceuticals. New York: Soc Nucl Med; 1979. p. 259-64.
172. 18F-5-fluorouridine, a new probe for measuring the proliferation of tissue in vivo Adv Enzyme Regul 20 1982 3 22
173. J. Toyohara, and Y. Fujibayashi Trends in nucleoside tracers for PET imaging of cell proliferation Nucl Med Biol 30 2003 681 685
174. 18F]FLT for imaging of cellular proliferation in vivo Nucl Med Biol 27 2000 1434 1456
175. X.B. Kong, Q.Y. Zhu, P.M. Vidal, K.A. Watanabe, B. Polsky, and D. Armstrong Comparisons of anti-human immunodeficiency virus activities, cellular transport, and plasma and intracellular pharmacokinetics of 3′-fluoro- 3′-deoxythymidine and 3′- azido-3′-deoxythymidine Antimicrob Agents Chemother 36 1992 808 818
176. 18F] FLT and positron emission tomography Nat Med 4 1998 1334 1336
177. 18F]FDG J Nucl Med 44 2003 1426 1431
178. K. Isidate Choline transport and choline kinase D.E. Vance Phosphatidylcholine metabolism 1989 CRC Press Boca Raton (FL) 9 32
179. K. Nakagami, T. Uchida, S. Ohwada, Y. Koibuchi, Y. Suda, and T. Sekine Increased choline kinase activity and elevated phosphocholine levels in human colon cancer Jpn J Cancer Res 90 1999 419 424
180. 11C]choline J Nucl Med 38 1997 842 847
181. 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer Cancer Res 61 2000 110 117
182. 18F-Fluorocholine: a new oncologic PET tracer J Nucl Med 12 2001 1815 1817
183. 11C-choline PET J Nucl Med 44 2003 331 335
184. 11C-choline PET J Nucl Med 41 2000 1507 1513
185. 11C-choline PET: first clinical experience Eur J Nucl Med 29 2002 1283 1288
186. 11C-Acetate PET imaging of prostate cancer J Nucl Med 43 2002 181 186
187. 18F]- Fluoroacetate, an analogue of C-11 acetate for tumor imaging J Nucl Med 44 2003 296p
188. J.A. Katzenellenbogen Estrogen and progestin radiopharmaceuticals for imaging breast cancer E.J. Pavlik Estrogens, progestins and their antagonists 1996 Birkhauser Boston 197 242
189. 18F-FDG in patients with progressive, metastatic prostate cancer J Nucl Med 45 2002 366 373
190. B.J. Vilner, C.S. John, and W.D. Bowen Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines Cancer Res 55 1995 408 413
191. I. Alnabulsi, R.H. Mach, L.M. Wang, C.A. Wallen, P.C. Keng, and K. Sten Effect of ploidy, recruitment, environmental factors, and tamoxifen treatment on the expression of sigma-2 receptors in proliferating and quiescent tumor cells Br J Cancer 81 1999 925 933
192. W.D. Bowen Sigma receptors: recent advances and new clinical potentials Pharm Acta Helv 74 2000 211 218
193. V. Caveliers, H. Everaert, T. Lahoutte, L.O. Dierickx, and C.S. John Labeled sigma receptor ligands: can their role in neurology and oncology be extended? Eur J Nucl Med 28 2001 133 135
194. 18F] labeled benzamides: high affinity sigma receptor ligands for PET imaging Nucl Med Biol 24 1997 333 340
195. 18F]fluorobenzamide: a potential ligand for PET imaging of sigma receptors Nucl Med Biol 24 1997 671 676
196. 18F]-1-(3-fluoropropyl)-4-(4- cyanophenoxy- methyl)piperidine-a potential selective sigma-1 receptor radioligand for PET Nucl Med Biol 24 1997 127 134
197. 18F]fluorobenzamide: a potential ligand for PET imaging of breast cancer Nucl Med Biol 27 2000 763 767
198. O.C. Boerman, W.J.G. Oyen, and F.H.M. Corstens Radio-labeled receptor-binding peptides: a new class of radiopharmaceuticals Semin Nucl Med XXX 2000 195 208
199. S.M. Okarvi Recent progress in fluorine-18 labeled peptide radiopharmaceuticals Eur J Nucl Med 28 2001 929 938
200. A. Nunn, K. Linder, and H.W. Strauss Nitroimidazoles and imaging hypoxia Eur J Nucl Med 22 1995 265 280
201. J.R. Ballinger Imaging hypoxia in tumors Semin Nucl Med 31 2001 321 329
202. J.S. Lewis, and M.J. Welch PET imaging of hypoxia Q J Nucl Med 45 2001 183 188
203. 18F]fluoromisonidazole: a pretherapy study of 37 patients Int J Radiat Oncol Biol Phys 36 1996 417 428
204. 18F]FETNIM) and PET using the tumor to plasma ratio Eur J Nucl Med 30 2003 101 108
205. 18F]fluoroetanidazole as a new marker for imaging tumour hypoxia with positron emission tomography Br J Cancer 90 2004 2232 2242
206. 18F]EF1 J Nucl Med 41 2000 327 336
207. 18F]EF5 Eur J Nucl Med 30 2003 259 266
208. 18F]-labeled EF3 [2-(2-nitroimidazol-1-yl)-N-(3,3,3- trifluoropropyl)-acetamide], a marker for PET detection of hypoxia Bioorg Med Chem 9 2001 665 675
209. 60Cu-ATSM Eur J Nucl Med 30 2003 844 850
210. J. Folkman Angiogenesis E. Braunwald A.S. Fauci D.L. Kasper S.L. Hauser D.L. Longo J.L. Jameson Harrison's textbook of internal medicine 15th edition 2001 McGraw-Hill New York 517 530
211. C. Van de Wiele, R. Oltenfreiter, O. De Winter, A. Signore, G. Slegers, and R.A. Dierckx Tumor angiogenesis pathways: related clinical issues and implications for nuclear medicine imaging Eur J Nucl Med 29 2002 699 709
212. 3 integrin expression using F-18 labeled RGD-containing glycopeptide and positron emission tomography Cancer Res 61 2001 1781 1785
213. 18F-Galacto-RGD and PET: initial results in patients J Nucl Med 45 2004 192P
214. 18F-labeled RGD peptide: initial evaluation for imaging brain tumor angiogenesis Nucl Med Biol 31 2004 179 189
215. 18F-squalamine of a mouse model of ovarian carcinoma overexpressing VEGF-164 J Nucl Med 44 2003 296P
216. F.G. Blankenberg, J.F. Tait, and H.W. Strauss Apoptotic cell death: its implications for imaging in the next millennium Eur J Nucl Med 27 2000 359 367
217. S.J. Martin, C.P. Reutelingsperger, A.J. McGahon, J.A. Rader, R.C. van Schie, and D.M. LaFace Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of βcl-2 and Abl J Exp Med 182 1995 1545 1556
218. 99mTc-HYNIC- Annexin V, a novel human recombinant annexin V for human application J Nucl Med 44 2003 947 952
219. 123I-labeled human recombinant annexin V Biomol Eng 17 2000 51 53
220. D.R. Collingridge, M. Glaser, S. Osman, H. Barthel, O.C. Hutchinson, and S.K. Luthra In vitro selectivity, in vivo biodistribution and tumor uptake of annexin V radiolabeled with a positron emitting radioisotope Br J Cancer 89 2003 1327 1333
221. 18F-labeled recombinant annexin-V derivative, for identification and quantification of apoptotic cells with PET Appl Radiat Isot 58 2003 201 207
222. 64Cu labeled annexin-V, positron emitting radiopharmaceuticals to study apoptosis J Labelled Comp Radiopharm 46 2003 S335
223. 18F]fluoroguanine derivatives: in vivo probes for imaging gene expression with PET Nucl Med Biol 27 2000 157 162
224. 18F]FHPG): a potential imaging agent of viral infection and gene therapy using PET Nucl Med Biol 23 1996 787 792
225. 18F]FHBG) for gene therapy Nucl Med Biol 28 2001 875 883
226. 18F]FHBG): a new potential imaging agent for viral infection and gene therapy using PET Nucl Med Biol 25 1998 175 180
227. 18F]FHBG Nucl Med Biol 31 2004 133 138
228. J.G. Tjuvajev, N. Avril, T. Oku, T. Sasajima, T. Miyagawa, and R. Joshi Imaging herpes virus thymidine kinase gene transfer and expression by positron emission tomography Cancer Res 58 1998 4333 4341
229. 18F]-FMAU) J Labelled Comp Radiopharm 45 2002 583 590
230. 18F]- FCAU), and their biological evaluation as markers for gene expression Nucl Med Biol 31 2004 399 405
231. 18F]-fluoropenciclovir: an improved reporter probe for imaging HSV-tk reporter gene expression in vivo using PET J Nucl Med 42 2001 96 105
232. 18F]FHBG) for in vivo measurement of suicide gene expression with PET J Nucl Med 42 2001 1682 1690
233. M.M. Alauddin, A. Shahinian, E.M. Gordon, and P.S. Conti Evaluation of 2′-deoxy-2′-fluoro-5-methyl-1-β-D- arabinofuranosyluracil (FMAU) as a potential gene imaging agent for HSV-tk expression in vivo Mol Imaging 1 2002 74 81
234. J.G. Tjuvajev, M. Doubrovin, T. Akhurst, S. Cai, J. Balatoni, and M.M. Alauddin Comparison of radiolabeled nucleoside probes (FIAU, FHBG, and FHPG) J Nucl Med 43 2002 1072 1083
235. 18F]FIAU, as potential PET agents for imaging cellular proliferation Nucl Med Biol 30 2003 215 224
236. 18F]FHBG: a reporter probe for imaging herpes simplex virus type-1 thymidine kinase reporter gene expression J Nucl Med 42 2001 1225 1234
237. A. Jacobs, J. Voges, R. Reszka, M. Lercher, A. Gossmann, and L. Kracht Positron-emission tomography of vector-mediated gene expression in gene therapy for gliomas Lancet 358 2001 727 729
238. 18F]-labeled 1,2-diacylglycerols: a new tracer for imaging second messenger system J Labelled Comp Radiopharm 35 1994 517 519
239. Y. Imahori, Y. Ohmori, R. Fujii, K. Matsumoto, and S. Ueda Rapid incorporation of carbon-11 labeled diacylglcerol as a probe of signal transduction in glioma Cancer Res 55 1995 4225 4229
240. T. Sasaki, A. Enta, T. Nozaki, S. Ishii, and M. Senda Carbon-11- forskolin: a ligand for visualization of the adenylate cyclase-related second messenger J Nucl Med 34 1993 1944 1948
241. 11C]-butyryl-2-palmitoyl-rac-glycerol in rats with myocardial infarction J Nucl Med 41 2000 2063 2068
242. 11C]rolipram for PET imaging of phosphodiesterase VI: in vivo binding, metabolism and dosimetry studies in rats Nucl Med Biol 28 2001 347 358
243. C.-Y. Shiue, A. Schmitz, R. Schirrmacher, G.G. Shiue, and A. Alavi Potential approaches for beta cell imaging with PET and SPECT Curr Med Chem-Immun Endoc and Metab Agents 4 2004 271 280
244. 18F]repaglinide): a promising radioligand for quantification of pancreatic β-cell mass with positron emission tomography (PET) Nucl Med Biol 31 2004 639 647
245. 11C]methoxy-repaglinide): a potential β-cell imaging agent Bioorg Med Chem Lett 14 2004 5205 5209
246. I.R. Sweet, D.L. Cook, A. Lernmark, C.J. Greenbaum, A.R. Wallen, and E.S. Marcum Systematic screening of potential β-cell imaging agents Biochem Biophys Res Commun 314 2004 976 983